For the 2024/25 season RSV protection is publicly funded for the following infants and children:
- Born in 2024 prior to the RSV season
- Born during the 2024/25 RSV season
- Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season with:
- Chronic lung disease (CLD), including bronchopulmonary dysplasia, requiring ongoing assisted ventilation, oxygen therapy or chronic medical therapy in the six months prior to the start of RSV season (Note: Children who were < 12 months of age and approved for coverage in the previous RSV season for chronic lung disease
and bronchopulmonary dysplasia remain eligible.)
- Hemodynamically significant congenital heart disease (CHD) requiring corrective surgery or are on cardiac medication for congestive heart failure or diagnosed with moderate to severe pulmonary hypertension
- Severe immunodeficiency
- Down syndrome/Trisomy 21
- Cystic fibrosis with respiratory involvement and/or growth delay
- Neuromuscular disease impairing clearing of respiratory secretions
- Severe congenital airway anomalies impairing the clearing of respiratory secretions
This product is now available in limited supply, with additional supply expecting in the coming weeks. This product is NOT currently available for purchase in the private market.
Please speak with your health care provider if you have questions regarding eligibility.